We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Finds Insufficient Data for Duchenne’s Drug’s Efficacy
Advisory Committee Finds Insufficient Data for Duchenne’s Drug’s Efficacy
An FDA advisory committee voted 10 to 1 that a muscular dystrophy drug candidate does not have enough supporting data to be considered effective, noting problems with interpreting data from clinical trials.